90.36
-0.71 (-0.78%)
| Previous Close | 91.07 |
| Open | 91.07 |
| Volume | 2,344,312 |
| Avg. Volume (3M) | 2,040,042 |
| Market Cap | 11,852,561,408 |
| Price / Sales | 11.63 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 0.00 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 180.00 (Leerink Partners, 99.20%) | Buy |
| Median | 132.50 (46.64%) | |
| Low | 110.00 (Evercore ISI Group, 21.74%) | Hold |
| Average | 135.42 (49.87%) | |
| Total | 11 Buy, 1 Hold | |
| Avg. Price @ Call | 103.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 24 Feb 2026 | 130.00 (43.87%) | Buy | 95.40 |
| BTIG | 20 Feb 2026 | 145.00 (60.47%) | Buy | 103.10 |
| Canaccord Genuity | 20 Feb 2026 | 135.00 (49.40%) | Buy | 103.10 |
| Citigroup | 20 Feb 2026 | 150.00 (66.00%) | Buy | 103.10 |
| Evercore ISI Group | 20 Feb 2026 | 110.00 (21.74%) | Hold | 103.10 |
| JP Morgan | 20 Feb 2026 | 130.00 (43.87%) | Buy | 103.10 |
| Leerink Partners | 20 Feb 2026 | 180.00 (99.20%) | Buy | 103.10 |
| Stifel | 20 Feb 2026 | 130.00 (43.87%) | Buy | 103.10 |
| TD Cowen | 20 Feb 2026 | 135.00 (49.40%) | Buy | 103.10 |
| Wells Fargo | 20 Feb 2026 | 125.00 (38.34%) | Buy | 103.10 |
| Baird | 17 Feb 2026 | 120.00 (32.80%) | Buy | 107.11 |
| Guggenheim | 26 Jan 2026 | 135.00 (49.40%) | Buy | 114.74 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SAIA JOHN G. | - | 84.86 | -3,970 | -336,894 |
| TARIQ MUSA | - | 85.70 | -116 | -9,941 |
| Aggregate Net Quantity | -4,086 | |||
| Aggregate Net Value ($) | -346,835 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 85.28 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TARIQ MUSA | Director | 16 Apr 2026 | Sell (-) | 116 | 85.70 | 9,941 |
| SAIA JOHN G. | Officer | 15 Apr 2026 | Disposed (-) | 3,970 | 84.86 | 336,894 |
| SAIA JOHN G. | Officer | 15 Apr 2026 | Option execute | 7,569 | - | - |
| TARIQ MUSA | Director | 15 Apr 2026 | Option execute | 250 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Guardant Health to Participate in Upcoming Investor Conferences |
| 02 Feb 2026 | Announcement | Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions |
| 29 Jan 2026 | Announcement | Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |